One COVID-19 vaccine is already being given to Americans. Another could win Emergency Use Authorization in only a few days. But that's just the beginning of the news for COVID-19 vaccine makers. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights talk about two other COVID-19 vaccine stocks with key results on the way.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Corrine Cardina: My last topic for us before we try to tackle a couple of Slido questions is turning to the companies that are next in line to cross this finish line, what do we know about the timeline for Johnson & Johnson (JNJ 1.49%) and AstraZeneca's (AZN 0.28%) phase 3 data?
Keith Speights: Let's start with Johnson & Johnson. Johnson & Johnson has kept their information a little closer to the vest than a lot of these companies. I think it's reasonable to expect that J&J will report their interim results from their phase 3 study sometime early next year. I've said it before, I'll say it again. I'm extremely interested in seeing what their efficacy will be. We have news coming from J&J early in 2021.
AstraZeneca is a little interesting because they could have their data from their current studies available around the same time frame as Johnson & Johnson. However, keep in mind that the higher efficacy for AstraZeneca was in a group that received a half dose then a full dose of their vaccine.
They didn't have that dosing regimen in their US study originally. They said they were going to add that dosing regimen to their US study. But the FDA requires two months of observation after the second dose.
It's going to be interesting to see with AstraZeneca. That could throw them off somewhat if they're going to wait to file EUA with the FDA until they have results from the group that could give them a higher efficacy. I think the verdict is still out when it comes to AstraZeneca.
